Abstract:

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and is often detected at advanced stages, limiting treatment options and adversely affecting patient outcomes. Recognized by the WHO as the leading cause of cancer-related deaths, NSCLC necessitates improved diagnostic and therapeutic strategies. Aloe-emodin (AE), a natural compound with known anticancer properties, has demonstrated efficacy in inducing apoptosis and inhibiting cell proliferation in various cancer types. This study investigates AE's potential in treating NSCLC by targeting the PI3K/Akt/mTOR signalling pathway, crucial for cancer cell survival and proliferation. A549 lung cancer cells were treated with varying concentrations of AE, and cell viability was assessed using the MTT assay. Molecular docking studies were conducted to explore AE's interactions with PI3K, Akt1, and mTOR. Gene expression levels of these proteins were analysed using RT-PCR. Results showed a concentration-dependent decrease in NSCLC cell viability, with significant reductions observed at 72 hours. RT-PCR analysis indicated the downregulation of PI3K, Akt1, and mTOR in AE-treated cells. Docking studies revealed strong binding affinities of AE to PI3K, suggesting its inhibitory potential. These findings highlight AE's promise as a therapeutic agent against NSCLC, warranting further investigation into its mechanisms and clinical applicability.

References:

[1].   Araghi M, Mannani R, Heidarnejad maleki A, Hamidi A, Rostami S, Safa SH, et al. 2023, Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell International, 23(1):1–26, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416536/.

[2].   Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 1(3):209-49, https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660.

[3].   Jovanoski N, Abogunrin S, Di Maio D, Belleli R, Hudson P, Bhadti S, et al.2023, Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC). Pharmacoeconomics, 1(11):1437–52, https://pubmed.ncbi.nlm.nih.gov/37389802/.

[4].   Korytowsky B, Radtchenko J, Nwokeji ED, Tuell KW, Kish JK, Feinberg BA.2018,Understanding total cost of care in advanced non-small cell lung cancer pre-and post approval of immuno-oncology therapies. American Journal of Managed Care, 24(20Suppl):S439-47, https://pubmed.ncbi.nlm.nih.gov/30362811/.

[5].   Thimmegowda NR, Park C, Shwetha B, Sakchaisri K, Liu K, Hwang J, et al.2015, Synthesis and antitumor activity of natural compound aloe emodin derivatives. Chemical Biology & Drug Design, 85(5):638–44, https://pubmed.ncbi.nlm.nih.gov/25323822/.

[6].   Jiang D, Ding S, Mao Z, You L, Ruan Y. 2021, Integrated analysis of potential pathways by which aloe-emodin induces the apoptosis of colon cancer cells. Cancer Cell International,21(1):1–12, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077783/.

[7].   Pecere T, Sarinella F, Salata C, Gatto B, Bet A, Dalla Vecchia F, et al. 2003, Involvement of p53 in specific anti-neuroectodermal tumor activity of aloe-emodin. International Journal of Cancer, 106(6):836–47, https://pubmed.ncbi.nlm.nih.gov/12918060/.

[8].   Li SW, Yang TC, Lai CC, Huang SH, Liao JM, Wan L, et al. 2014, Antiviral activity of aloe-emodin against influenza A virus via galectin-3 up-regulation. European Journal of Pharmacology, 738:125–32, https://pubmed.ncbi.nlm.nih.gov/24877694/.

[9].   Li T, Lu Y, Zhang H, Wang L, Beier RC, Jin Y, et al. 2021, Antibacterial Activity and Membrane-Targeting Mechanism of Aloe-Emodin Against Staphylococcus epidermidis. Frontiers in Microbiology, 12:621866, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2021.621866/full.

[10].  Xiao-li PAN, Xue-bo LI, Bing WU.2021, Study on the Antioxidant Activity of Aloe-Emodin Metal Complex. Journal of Sichuan University (Medical sciences). 52(2):241–7, https://pubmed.ncbi.nlm.nih.gov/33829698/.

[11].  Park MY, Kwon HJ, Sung MK. 2009, Evaluation of aloin and aloe-emodin as anti-inflammatory agents in aloe by using murine macrophages. Bioscience Biotechnology Biochemistry.73(4):828–32, https://pubmed.ncbi.nlm.nih.gov/19352036/.

[12].  Shen F, Ge C, Yuan P.2020, Aloe-emodin induces autophagy and apoptotic cell death in non-small cell lung cancer cells via Akt/mTOR and MAPK signaling. European Journal of Pharmacology. 886:173550, https://pubmed.ncbi.nlm.nih.gov/32926915/.

[13].  Şeker Karatoprak G, Küpeli Akkol E, Yücel Ç, Bahadır Acıkara Ö, Sobarzo-Sánchez E. 2022, Advances in Understanding the Role of Aloe Emodin and Targeted Drug Delivery Systems in Cancer. Oxidative Medicine and Cellular Longetivity. 2022:7928200, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789423/.

[14].  Wang H, Guo M, Wei H, Chen Y. 2023, Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduction and Targeted Therapy. 8(1):92, https://pubmed.ncbi.nlm.nih.gov/36859359/.

[15].  Peng Y, Wang Y, Zhou C, Mei W, Zeng C. 2022, PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Frontiers in Oncology. 12:819128, https://pubmed.ncbi.nlm.nih.gov/35402264/.

[16].  Szwed A, Kim E, Jacinto E. 2021,Regulation and metabolic functions of mTORC1 and mTORC2. Physiological Reviews. 101(3):1371–426, https://pubmed.ncbi.nlm.nih.gov/33599151/.

[17].  Wiese W, Barczuk J, Racinska O, Siwecka N, Rozpedek-Kaminska W, Slupianek A, et al. 2023,PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities. Cancers. 15(21):5297, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648005/.

[18].  Zhu M, He Q, Wang Y, Duan L, Rong K, Wu Y, et al. 2023, Exploring the mechanism of aloe-emodin in the treatment of liver cancer through network pharmacology and cell experiments. Frontiers in Pharmacology. 14:1238841, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1238841/full.

[19].  Li T, Shi L, Liu W, Hu X, Hui Y, Di M, et al. 2022, Aloe-Emodin Induces Mitochondrial Dysfunction and Pyroptosis by Activation of the Caspase-9/3/Gasdermin E Axis in HeLa Cells. Frontiers in Pharmacology. 13:854526, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157280/.

[20].  Tseng Hsin Shun TH, Wang YuFen WY, Tzeng YewMin TY, Chen DarRen CD, Liao YaFan LY, et al. 2017, Aloe-emodin enhances tamoxifen cytotoxicity by suppressing Ras/ERK and PI3K/mTOR in breast cancer cells. The American Journal of Chinese Medicine. 45(02):337-50, https://www.worldscientific.com/doi/abs/10.1142/S0192415X17500215.

[21].  Sharma D, Kumar N, Mehrotra T, Pervaiz N, Agrawal L, Tripathi S, et al. 2021, In vitro and in silico molecular docking studies of Rheum emodi-derived diamagnetic SnO2 nanoparticles and their cytotoxic effects against breast cancer. New Journal of Chemistry. 45:1695–711, https://pubs.rsc.org/en/content/articlelanding/2021/nj/d0nj04670a